Ajinomoto Bio-Pharma Services
Platform Technologies

Based on the corporate message “Eat Well, Live Well.”, Ajinomoto Co., Inc. has been scientifically pursuing the possibilities of amino acids to aim for future growth by creating new value through sustainable and innovative solutions for communities and society.

As its pharmaceutical arm, Ajinomoto Co., Inc. owns Ajinomoto Bio-Pharma Services as a fully integrated contract development and manufacturing organization (CDMO) with sites in Belgium, United States, Japan, and India, providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates.

In addition, Ajinomoto Co., Inc. and Ajinomoto Bio-Pharma Services offers a broad range of innovative platform technologies illustrated in this website and capabilities for pre-clinical and pilot programs to commercial quantities, including AJIPHASE® oligonucleotide manufacturing technology, CORYNEX®/TALAMAX® protein expression system, AJICAP® site-specific conjugation technology for ADC, and continuous flow manufacturing and more.

Ajinomoto and Ajinomoto Bio-Pharma Services offers a broad range of innovative platform technologies from pre-clinical and pilot programs to commercial quantities.

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization (CDMO) with sites in Belgium, United States, Japan, and India, providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates.

For further information, please contact us using the link below and an Ajinomoto Bio-Pharma Services representative will contact you.